LCH is designated as a rare disease. It predominantly affects young children, with the median age of diagnosis being around 3 years old.

• Children: Incidence is estimated between 2 to 10 cases per 1 million children annually.

• Adults: Exceedingly rare, with an estimated incidence of 1 to 2 cases per 1 million annually.

• Gender: There is a slight male predominance, with a male-to-female ratio of roughly 2:1.

LCH has been debated as either an inflammatory condition or a cancer. The discovery of recurrent genetic mutations has led to some oncologists to classify it as a neoplastic (cancerous) disorder, though neoplasms can be benign or malignant.

The disease is driven mainly by mutations in genes of the RAS-RAF-MEK-ERK signaling pathway, which regulate cellular growth, differentiation and inflammatory signaling.

• BRAF V600E gene mutation associated with growth abnormalities: Found in approximately 50% of LCH patients. 

• MAP2K1, ARAF and RAS gene mutations: Found in up to 50% of patients who do not have the BRAF mutation.

• Environmental triggers: In cases of isolated Pulmonary Langerhans Cell Histiocytosis (PLCH), cigarette smoking is identified as a primary environmental trigger and is present in nearly 90% of PLCH patients. Other environmental factors, such as exposure to viral or bacterial infections during pregnancy, may also raise the risk of developing LCH.

The precise initiating cause is unknown. LCH is not generally an inherited disorder. Instead, it is usually driven by acquired (somatic) mutations in white blood cells that develop in the bone marrow.

Symptoms vary widely depending on which organs are affected, ranging from localized lesions to multiorgan involvement.

• Bone is the most frequently affected organ (about 80% of cases). Symptoms may include pain, anemia, recurrent infections, fever, easy bruising, tenderness, swelling and fractures. Lesions at the base of the skull can affect vision, hearing and pituitary function. 

• Skin (dermatitis, papules, rash, itching, ulcerations, nail loss), gastrointestinal tract, and oral/jaw involvement (loose teeth, gum problems) are recognized presentations in about a third of LCH patients.

• Liver (enlargement, jaundice, abnormal liver tests), spleen, lymph nodes, and bone marrow may also be affected, and are associated with a worse prognosis.

• Lung or pulmonary LCH (dry cough, shortness of breath, chest pain, reduced exercise tolerance) is more prevalent in adults, and people who smoke are at higher risk.

• Central nervous system involvement may cause headaches, balance and coordination problems, ataxia, tremor, seizures, cognitive changes, neurodegeneration and endocrine abnormalities.

As LCH symptoms can overlap with those of more common conditions, it is often misdiagnosed. Diagnosis requires a multi-step approach including clinical assessment, tissue pathology testing, imaging and molecular testing. 

A biopsy of an accessible lesion, often from skin, bone or lymph nodes, is examined for inflammatory cells and LCH cells with cytoplasmic inclusions positive for CD1a and CD207 (langerin), and S100 protein dendritic cell markers. The biopsied tissue can be tested for BRAF and MAPK pathway mutations. Imaging and blood work can help determine if the disease is single system or multi-system (involving two or more organs).

Treatment is highly individualized based on age, disease extent, molecular characteristics and whether "risk organs" (liver, spleen, or bone marrow) are involved.

• Single-System Disease: Often requires minimal intervention. Isolated skin lesions might be treated with topical steroids or topical nitrogen mustard. Isolated bone lesions might be surgically removed or monitored closely. For isolated pulmonary LCH, smoking cessation is paramount and can independently induce complete remission.

• Multi-System Disease (Low Risk): Typically managed with systemic therapies. Standard first-line regimens often include systemic steroids combined with chemotherapy drugs like vinblastine, cytarabine, or methotrexate.

• Multi-System Disease (High Risk): Involves more aggressive chemotherapy regimens (like cladribine or cytarabine). In selected severe cases, hematopoietic (blood-forming) stem-cell transplantation may be considered.

• Targeted Therapy: For patients with severe or refractory disease who possess the BRAF V600E mutation, targeted BRAF inhibitors (such as vemurafenib) have shown significant efficacy. MEK inhibitors such as trametinib or cobimetinib can be used for selected MAPK-driven disease.

Overall survival rates for LCH in developed countries for LCH are excellent—often exceeding 95%. The prognosis heavily depends on the patient's age and disease spread:

• Single-system disease has an exceptional prognosis with virtually a 100% survival rate, and sometimes lesions regress spontaneously.

• Multi-system disease without risk organ involvement has a highly favorable survival rate, though patients may face recurrent "reactivations" of the disease and permanent sequelae (like chronic diabetes insipidus or hearing loss).

• Multi-system disease with risk organ involvement (especially in infants under 1 year of age) carries the highest mortality risk, with historical survival rates close to 50%, though targeted inhibitors and modern chemotherapy have been improving these odds.

Long-term complications can be significant, including pituitary hormone deficiencies such as diabetes insipidus, growth abnormalities, chronic lung disease, hearing impairment, bone deformity, neurologic/neurodegenerative complications, and chronic pain and fatigue. Thus, long-term follow-up is essential even after apparent remission.

1. Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J. 2013. “Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.” Pediatr Blood Cancer. 60(2):175-84. doi: 10.1002/pbc.24367. Epub 2012 Oct 25. PMID: 23109216; PMCID: PMC4557042.

2. Tillotson CV, Reynolds SB, Patel BC. 2024. “Langerhans Cell Histiocytosis.” In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Available from: https://www.ncbi.nlm.nih.gov/books/NBK430885/.

3. NORD (National Organization for Rare Disorders):  Langerhans Cell Histiocytosis.

4. Merck Manual Professional Edition — Langerhans Cell Histiocytosis: https://www.merckmanuals.com/professional/hematology-and-oncology/histiocytic-syndromes/langerhans-cell-histiocytosis.

5. Cleveland Clinic:  https://my.clevelandclinic.org/health/diseases/17156-langerhans-cell-histiocytosis.